Abstract
Bopindolol is a potent and specific beta-adrenoceptor antagonist with partial agonist activity. In animal experiments it blocks both beta 1- and beta 2-adrenoceptors and possesses a long duration of action. In the present study in healthy volunteers bopindolol was about ten times more potent than pindolol in reducing isoprenaline-induced and exercise-induced tachycardia. In experiments on exercise-induced tachycardia an oral dose of 2 mg produced a near maximum reduction of exercise heart rate, occurring within 2 to 3 h of administration. With higher doses (up to 12 mg) the maximum effect was reached earlier (between 1 and 2 h). The long duration of action of bopindolol observed in animal studies was confirmed in man. Twenty-four hours after 4 and 10 mg bopindolol more than 2/3 of the maximum effect was still present. After 48 h 38% of the maximum effect of 4 mg and 50% of that of 12 mg remained. Even at 72 and 96 h exercise-induced tachycardia was still significantly lowered after both doses of the drug. When bopindolol was administered once daily for 5 days there was a slight increase in the maximum reduction of exercise-induced tachycardia during treatment with 1 mg/day but not with 4 mg/day, which produced a near maximum effect.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Aellig W. H. beta-Adrenoceptor blocking activity and duration of action of pindolol and propranolol in healthy volunteers. Br J Clin Pharmacol. 1976 Apr;3(2):251–257. doi: 10.1111/j.1365-2125.1976.tb00600.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Clark B. J., Saameli K., Troxler F. Proceedings: Pharmacological studies with LL 21-945, a new beta-adrenoceptor blocking agent with a long duration of action. Br J Pharmacol. 1974 Sep;52(1):123P–123P. [PMC free article] [PubMed] [Google Scholar]
- Dollery C. T., Dargie H. J., Sassard J., Cuisinaud G. Concentration-effect relationships with FM 24: a new long acting beta-adrenergic receptor antagonist. Br J Clin Pharmacol. 1983 Jun;15(6):707–713. doi: 10.1111/j.1365-2125.1983.tb01554.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hulthén U. L., van Brummelen P., Amann F. W., Bühler F. R. Antihypertensive efficacy of the new long-acting beta-blocker bopindolol as related to age. J Cardiovasc Pharmacol. 1983 May-Jun;5(3):426–429. doi: 10.1097/00005344-198305000-00012. [DOI] [PubMed] [Google Scholar]
- Platzer R., Galeazzi R. L., Niederberger W., Rosenthaler J. Simultaneous modeling of bopindolol kinetics and dynamics. Clin Pharmacol Ther. 1984 Jul;36(1):5–13. doi: 10.1038/clpt.1984.130. [DOI] [PubMed] [Google Scholar]
- Porter A. M. Drug defaulting in a general practice. Br Med J. 1969 Jan 25;1(5638):218–222. doi: 10.1136/bmj.1.5638.218. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Turner D. R., Goodwin F. J., Knight A. R., Littlejohns D. W., Sharman V. L., Vere D. W. Bopindolol: a new long acting beta-receptor antagonist; its effects on haemodynamics, and on the renin response to tilting. Br J Clin Pharmacol. 1984 Mar;17(3):295–299. doi: 10.1111/j.1365-2125.1984.tb02344.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- van Brummelen P., Bühler F. R., Amann F. W., Bolli P. Effects of a new long-acting beta-blocker bopindolol (LT 31-200) on blood pressure, plasma catecholamines, renin and cholesterol in patients with arterial hypertension. Eur J Clin Pharmacol. 1982;22(6):491–493. doi: 10.1007/BF00609620. [DOI] [PubMed] [Google Scholar]